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Abstract
Objective: Hemangiopericytoma is a rare and aggressive meningeal tumor. Although surgical resection is the
standard treatment, hemangiopericytomas often recur with high incidences of metastasis. The purpose of this
study was to evaluate the role of CyberKnife stereotactic radiosurgery (CK) in the management of recurrent,
metastatic, and residual hemangiopericytomas.
Methods: In a review of the Stanford radiosurgery database between 2002 and 2009, the authors found 14
patients who underwent CK therapy for recurrent, metastatic, and residual hemangiopericytomas. A total of 24
tumors were treated and the median patient age was 52 years (range 29-70 years) at the time of initial CK therapy.
The median follow-up period was 37 months (10-73 months) and all patients had been previously treated with
surgical resection. Mean tumor volume was 9.16 cm
3 and the mean marginal and maximum radiosurgical doses to
the tumors were 21.2 Gy and 26.8 Gy, respectively.
Results: Of the 24 tumors treated, 22 have clinical follow-up data at this time. Of those 22 tumors, 12 decreased in
size (54.5%), 6 remained unchanged (27.3%), and 4 showed recurrence (18.2%) after CK therapy. Progression-free
survival rate was 95%, 71.5%, and 71.5% at 1, 3, and 5 years after multiple CK treatments. The 5-year survival rate
after CK was 81%.
Conclusions: CK is an effective and safe management option for hemangiopericytomas. The current series
demonstrates a tumor control of 81.8%. Other institutions have demonstrated similar outcomes with stereotactic
radiosurgery, with tumor control ranging from 46.4% to 100%.
Background
Hemangiopericytomas (HPCs) are rare vascular tumors
arising from Zimmerman pericytes associated with capil-
lary walls. Central nervous systems HPCs are rare and
account for 0.4% of primary CNS tumors and 2.4% of
meningiomas[1,2]. Both clinically and radiographically,
hemangiopericytomas resemble meningiomas but are
known for their aggressiveness, high recurrence rates,
and propensity for extracranial metastasis. Patients with
HPCs present with a wide spectrum of symptoms,
dependent upon location and histologic grade of the
tumor.
T r e a t m e n to fC N SH P C si sa g g r e s s i v ea n dc o n s i s t so f
gross total resection combined with adjuvant radiother-
apy[3]. Given the proposed cellular origin, dural sinus
invasion, anatomic inaccessibility, and high vascularity
of HPCs, gross total resection is often not sufficient.
Maximal treatment consisting of gross total resection
and radiotherapy conveys a mean survival of approxi-
mately 84 months from diagnosis[4].
Due to the potential for residual and recurrent tumor,
stereotactic radiosurgery is well suited for post-operative
adjuvant therapy, particularly for inaccessible locations
[5]. The role of Gamma Knife (GKS) and CyberKnife
(CK) in the treatment of hemangiopericytomas has been
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from 46 - 100%[3,6-11]. Here within we report the Stan-
ford University experience using CyberKnife stereotactic
radiosurgery to treat fourteen patients with residual,
metastatic, or recurrent CNS hemangiopericytomas.
Materials and methods
Patient Population
Fourteen patients were treated with CyberKnife stereo-
tactic radiosurgery between the years 2002 and 2009 at
Stanford University Medical Center. All patients were
enrolled with approval from the Stanford Institutional
Review Board (IRB) and in accordance with the Helsinki
Declaration. Six patients were male (43%) and eight were
female (57%) with a median age of 52 years (range 29 -
70 years) at the time of initial CK therapy (Table 1). All
CNS HPCs were documented as residual, metastatic, or
recurrent, post-resection lesions. Seven patients had
undergone two or more surgical resections while seven
patients had undergone only one prior operation. Nine
patients had received prior cranial irradiation. Presenting
symptoms correlated with lesion location and included
headache, seizures, visual dysfunction, motor weakness
and tandem gait. The mean time to CK treatment post-
surgery was 7.6 years (range 1 month - 16 years).
Tumor Characteristics
In total, the fourteen patients harbored twenty-four
HPCs. Mean tumor volume was 9.16 cm
3 (range 0.03 -
56.7 cm
3). Of the twenty-four total tumors treated, six-
teen tumors required a single session treatment, four
required two sessions, and four required three sessions
or more. Tumors were located in a myriad of locations,
including supra and infra-tentorial as well as spinal
(Table 2).
Treatment and Follow-up Evaluation
All fourteen patients and twenty-four tumors were trea-
ted with CyberKnife stereotactic radiosurgery (Accuray,
Inc., Sunnyvale, CA). Patients were placed on the treat-
ment bed and a previously designed facial thermoplastic
mask was fitted for stabilization. Patients were then
transferred to a CT scanner (Lightspeed; General Elec-
tric, Milwaukee, WI), where 125 ml of Omnipaque con-
trast was administered to obtain 1.25-mm slices of the
lesion and its surrounding location. Patients then under-
went a stereotactic MRI scan (2.0 mm slice thickness)
with gadolinium contrast, which was then fused to the
stereotactic CT scan. Tumor volume was carefully con-
toured and inverse treatment planning was performed
to achieve a conformal treatment plan that minimized
dose observed by adjacent eloquent structures (Figure
1).
For spinal treatments prior to 2005, patients first
underwent implantation of either straight gold fiducials
or stainless steel screws for tracking of spinal bony land-
marks. Following implantation, the patient returned
for a treatment planning CT. More recently, the
Table 1 Summary of Patient Characteristics
Ptn. Age at onset
and gender
Clinical
presentation
No. of
surgery
before CK
Radiation
therapy before
CK
Site Grade Time to CK
post-surgery
No. of CK
treatments
Follow-up
(months)
1 43 M HA, Vis 1 N Torcular 3 2 yrs 1 73
2 39M Vis 2 54Gy Parasellar - 16 yrs 2 36, 64
3 58M Leg weak 2 45Gy T6-8 3 6 yrs 1 37
4 47M HA, Ataxia, Vis 1 N Parafalcine 1 1 mo 1 37
5 42F Leg weak, Sz 2 N Parafalcine - 10 yrs 1 39
6 29F HA, Hand weak 1 N Tentorium 1 1 mo 3 53, 30, 10
7 47F Sen loss, Vis 1 GK C- T- spine - 10 yrs 1 26, 45
8 69F Foot drop 1 N Parafalcine 2 1 mo 1 41
9 38M HA, Sz 1 50.4Gy Left middle
fossa
- 9 mo 1 59
10 51F Left buttock pain 4 Y Lumbar spine - 16 yrs 3 15
11 41F HA, Vis 2 59.4Gy Rt Inf.
Cerebellar
3 5 yrs 1 30
12 53F Numbness, facial
pain, diplopia
2 Y Rt temporal,
Cav Sinus
- 14 yrs 3 -
13 38F Left facial palsy,
tandem gait
2 54 Gy Pineal space,
Left Tentorium
- 15 yrs 2 -
14 35M HA 1 Y Posterior Fossa - 12 yrs 2 15
(HA, headache; Vis, visual deficits; Sz, seizure; N, none; Y, prior radiation but no dosage available; GK, Gamma Knife)
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(Accuray Inc., Sunnyvale, CA) has eliminated the use of
fiducial implantation. Instead, the system localizes spinal
targets by direct reference to the adjacent vertebral
structures.
During the actual treatment, the CyberKnife treatment
algorithm places the LINAC at a determined position,
using real-time imaging to locate the target and adjust
for movements. The radiation beam is then delivered
and the process repeated at various preset nodes sur-
rounding the patient. Therefore, the target position is
continually updated using x-ray image-to-image correla-
tion, obviating the need for skeletal fixation to localize
the target. The precision of localization is 0.3 mm, com-
parable with that which can be achieved by frame-based
techniques.
Of the fourteen patients treated, follow-up data was
available for twelve patients, accounting for a total of
twenty-two tumors. Radiographic follow-up evaluation
included gadolinium-enhanced MR images obtained
every 4 months for the 1
st year after treatment, every 6
months during the 2
nd year, and annually thereafter.
Clinical follow-up examination was conducted at the
same intervals. The median clinical and radiographic
follow-up period was 37 months (range 10-73 months).
Results
Imaging Outcome
T h em e a nt u m o rv o l u m ew a s9 . 1 6c m
3 and the mean
marginal and maximum radiosurgical doses to the
tumors were 21.2 Gy (16 - 30 Gy) and 26.8 Gy (21.9 -
36.9 Gy), respectively. The mean isodose line was 77.5%
(Table 3). Treatment regimens vary based on size of
treated tumor, location to critical structures, and history
of prior radiation. In this series, all patients with brain
hemangiopericytomas who were treated with more than
one session had their hemangiopericytoma located next
to the brainstem, cavernous sinus, or optic pathways. A
single lumbar spine hemangiopericytoma was treated in
three sessions due to tumor size. Out of the twenty-four
tumors treated, twenty-two have clinical follow-up data
at this time. Of those twenty-two tumors, follow-up
MRI showed twelve decreased in size (54.5%), six
remained unchanged (27.3%), and four recurred or
Table 2 Summary of CyberKnife Radiosurgery Dosimetry
Ptn. Age
at CK
Tumor
vol (cc)
Site Marginal
dose (Gy)
Isodose
Line (%)
Fractions Dmax
(Gy)
% Target volume
treated at/above dose
Conformality
index
Tumor Control
At last F/U
1 45 7.0 Torcular 30 75 1 25.32 97 1.38 R
2 52 3.62 Tentorium 22 80 3 27.5 96.5 1.33 D
55 10.97 Petroclival 22 78 2 28.21 97 1.56 R
3 64 1.74 T6 24 78 3 30.77 96 1.47 R
4 47 3.5 Parafalcine 16 72 2 21.92 98 1.26 S
5 52 10.89 Parafalcine 20 73 2 27.4 97 1.46 S
6 29 1.5 Cav. Sinus 18 1 22.14 D
33 1.12 Cav sinus 30 83 5 36.14 99 1.34 D
37 0.97 Med. temp 20 76 1 26.3 99 1.21 R
7 57 0.23 C1 24 86 1 27.9 1.11 D
59 0.16 C3-4 18 75 1 D
60 0.03 T1 20 89 1 22.47 95 3.4 D
0.07 T6 20 79 1 25.32 95 2.68 D
0.06 T11 20 78 1 25.65 96 3.4 D
8 70 5.72 Parafalcine 22 79 1 27.85 1.6 D
9 39 21.8 Left middle
fossa
16 77 1 21.92 97 1.1 S
10 67 39.8 L1 20 70 1 28.17 95 1.31 D
67 0.99 L2 16 77 1 20.78 95 1.79 D
67 8.52 L4 16 77 1 20.78 99 1.95 D
11 46 0.236 Rt. Inf Cerebellar 24 74 1 32.45 98.7 1.25 S
12 67 14.36 Rt. Mid Fossa 27 73 3 36.99 95.2 1.56 -
13 53 16.74 Pineal space,
Left Tentorium
22 77 2 28.57 96.6 1.57 -
14 47 56.7 Posterior 21 76 1 27.63 95.1 1.19 S
13.2 fossa 21 80 1 26.25 97.8 1.27 S
(R, recurrence; S, stable; D, decreased size)
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control rate was 81.8%. There does not appear to be a
correlation between treatment dose, tumor volume, and
tumor response in these patients. There was no radiolo-
gical evidence of edema or necrosis in the tissue adja-
cent to the tumor in any patient in this series.
Clinical Outcome
Clinical symptoms were followed in all twelve patients.
Of those with adequate follow up data, one patient
reported resolution of headaches, eleven indicated no
change in symptoms and zero patients described wor-
sening of initial clinical presentation. All patients pre-
senting with cranial nerve deficits remained as such
with no improvement or worsening.
The patient with initial decrease (36 months follow-
up) and subsequent increase in tumor size (64 months)
had findings consistent with an ischemic event which
left him with cognitive changes. The patient with docu-
mented tumor progression despite radiosurgery has
since undergone three additional open surgeries to
excise the anaplastic hemangiopericytoma. Unfortu-
nately, his operations were complicated by hemorrhage
and postoperative CSF leak, and his recurrent disease
continues to cause visual decline and fatigue. Overall,
the progression-free survival rate was 95%, 71.5%, and
71.5% at 1, 3, and 5 years after multiple CK treatments.
The 5-year survival rate after CK treatment was 81%.
Discussion
CNS hemangiopericytomas are malignant CNS lesions
that exhibit aggressive behavior and are associated with
high rates of local recurrence and distant metastasis.
Surgical resection is the initial treatment of choice and
carries an operative mortality of 9-24%[12,13].
In a recent systematic review of published literature by
Rutkowski et al., several important prognostic factors
influencing hemangiopericytoma mortality rates were
identified[14]. Among the 563 patients reviewed, the
overall median survival was 13 years, with 1-, 5-, 10-,
and 20-year survival rates of 95%, 82%, 60%, and 23%,
respectively. Gross total resection alone was associated
with a median survival of 13 years, whereas subtotal
resection resulted in a median survival of 9.75 years.
Interestingly, in this report, postoperative adjuvant
radiation was not associated with a superior survival
benefit. Patients receiving >50 Gy of radiation had
Figure 1 CyberKnife contour for Patient 14, a forty-seven year
old male who was treated for a 56.7 cm
3 in the posterior
fossa. A single fraction at marginal dose of 21 Gy and maximum
dose of 27.6 Gy was used. The isodose line was 76% and the
conformity index was1.19. At 15 months follow-up, the tumor was
stable.
Table 3 Summary of Patient Characteristics and
CyberKnife Dosimetry
Number of Patients 14
Male 6 (43%)
Female 8 (57%)
Number of Tumors 24
Number of Tumors with Follow-Up 22
Median Age 52 years (29 - 70 years)
Median Follow-Up 37 months (10 - 73 months)
Mean Tumor Volume 9.16 cm
3 (0.03 - 56.7 cm
3)
Mean Marginal Dose 21.2 Gy (16 - 30 Gy)
Mean Maximum Dose 26.8 Gy (21.9 - 36.9 Gy)
Mean Isodose Line 77.5% (72 - 89%)
Mean Time to CK Post Surgery 7.6 years (1 month - 16 years)
Tumor Reduction 12 (54.5%)
Tumor Stable 6 (27.3%)
Tumor Recurrence 4 (18.2%)
Total Tumor Control 18 (81.8%)
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posterior fossa had a median survival of 10.75 vs. 15.6
years for those with tumors located elsewhere.
The primary challenge with surgical resection alone is
the high rate of postoperative recurrence. Studies have
shown a median rate of approximately 12 months.
Although multiple resections are feasible, the appreci-
able morbidity associated with each intervention makes
this option unattractive. Stereotactic radiosurgery com-
bines the efficacy of resection with the more minimal
rate of radiotherapy-induced morbidity. Some authors
have asserted that the highly vascular nature of these
tumors likely increases their favorable response to treat-
ment[15]. The steep dose gradient achieved with stereo-
tactic radiosurgery minimizes unintended radiation to
eloquent structures[6].
External Beam Radiotherapy Outcomes
External-beam radiotherapy has been used as adjuvant
therapy for the treatment of local recurrences, often fol-
lowing surgical resection. At a focal fractionated dose of
50 Gy, studies have shown a significant increase in the
length of time to tumor recurrence[1,7]. Dufour and
colleagues demonstrated that postoperative external
beam radiotherapy decreased the local recurrence rate
to 12.5% compared to 88% after surgery alone[7].
Guthrie et al. reported that radiation therapy after surgi-
cal resection extended the mean time to recurrence
from 34 to 75 months and extended survival from 62 to
92 months[1]. Glaholm and colleagues noted that even
in those patients who had undergone resection pre-
viously, megavoltage photon irradiation alone improved
neurological performance in 38% of patients, based on
the Karnofsy performance score[16]. The authors of
subsequent reports have also documented the benefit of
radiotherapy in those previously treated with surgery,
even when a gross-total resection had been achieved.
Most recently, Shiariti and colleagues reported on 39
patients who underwent microsurgical resection with a
mean follow-up period of 123 months[17]. External-
beam radiation therapy extended the disease-free inter-
val from 154 months to 254 months but was not effec-
tive in preventing metastasis. In those patients with
EBRT and complete resection, the mean recurrence-free
interval was found to be 126.3 months longer and over-
all survival 126 months longer than without EBRT.
Stereotactic Radiosurgery
Eleven published studies (including this current series)
on the use of stereotactic radiosurgery for recurrent and
residual hemangiopericytomas have been reviewed in
Table 4. Between the years of 1987 and 2010, a total of
137 patients with 241 lesions were treated with stereo-
tactic radiosurgery and reported in the literature. For
these lesions, the mean prescription dose was 16.2 Gy to
the tumor margin, the mean follow-up period of 37.2
months, and the mean tumor control rate of 81.3%
[3,6,8-11,15,16,18-20]. Since hemangiopericytomas are
rare tumors, and many of them are treated with conven-
tional radiation, our series size (fourteen patients with
twenty-two tumors) is reasonable. As compared with
several prior studies summarized in Table 4, it is notable
that our study contributes to previous CyberKnife series
on this rare tumor.
In 1993, Coffey and colleagues from the Mayo Clinic
provided the first preliminary SRS report for the treat-
ment of hemangiopericytomas[15]. Five patients with
eleven tumors were treated with GKS. At a mean
Table 4 Published Studies on Stereotactic Radiosurgery for Hemangiopericytoma
Series Institution Study period Treatment
Modality
No. of Patients/
Lesions
Mean Marginal
dose (Gy)
Mean Follow up
(months)
Tumor control
at last FU (%)
Coffey 1993[15] Mayo Clinic 1990-1992 Gamma Knife 5/11 15.5 14.8 81.8
Galanis 1998[18] Mayo Clinic 1976-1996 Gamma Knife 10/20 12-18 6-36 100*
Payne 2000[10] U of Virginia 1991-1999 Gamma Knife 10/12 14 24.8 75
Sheehan 2002[3] U of Pittsburgh 1987-2001 Gamma Knife 14/15 15 31.3 80
Chang 2003[6] Stanford 1992-2002 LINAC,
CyberKnife
8/8 20.5 44 75
Ecker 2003[8] Mayo Clinic 1980-2000 Gamma Knife 15/45 16 45.6 93^
Kano 2008[20] U of Pittsburgh 1989-2006 Gamma Knife 20/29 15 37.9 72.4
Sun 2009[11] Beijing Neu. Ins. 1994-2006 Gamma Knife 22/58 13.5 26 89.7
Iwai 2009[19] Osaka City Hosp 1994-2003 Gamma Knife 8/13 15.1 61 100
Olson 2010[9] U of Virginia 1989-2008 Gamma Knife 21/28 17 69 46.4
Veeravagu 2010 Stanford 2002-2009 CyberKnife 14/22 21.2 37 81.8
*Tumors responded to GKS with decrease or stability in volume, but effect lasted less than 1 year in majority of patients. Study also includes the five patients
from Coffey et al. 1993 manuscript.
^Also includes five patients from Coffey et al. 1993 manuscript.
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period of 14.8 months, the authors reported a tumor
control rate of 81.8%. Galanis and colleagues added five
more patients to the Coffey series for a total of 20
hemangiopericytomas[18]. Seven of the ten patients had
previously undergone radiotherapy (dose range 3060-
6400 cGy, median 5580 cGy) and all ten had undergone
at least one prior surgical resection. Fourteen of the
hemangiopericytomas decreased in size, four disap-
peared radiographically, and two were stable in size.
Payne et al. reported on ten patients with twelve
lesions who had undergone treatment with GKS[10].
Nine of the patients had undergone prior craniotomies
(mean number of surgeries 2.9) and four patients had
undergone prior fractionated radiotherapy. With a mean
peripheral dose of 14 Gy and mean follow-up period of
24.8 months, the authors demonstrated a 75% tumor
control rate. Four of the nine tumors that decreased in
size, however, subsequently increased in size after a
mean of 22 months post-radiosurgery.
Sheehan et al. published a series on fourteen patients
with fifteen hemangiopericytomas treated with GKS[3].
Twenty-seven prior surgical resections had been con-
ducted in this population; seven patients had previously
undergone radiotherapy. The marginal radiosurgery
doses ranged from 11 to 20 Gy and the mean follow-up
period was 31.3 months. At last follow-up, tumor
regression was demonstrated in 80% of the fifteen
tumors. Despite the effective local control rate, 29% of
the patients developed remote lesions, indicating that
radiosurgery provided little protection from metastatic
spread. Similarly, other studies have indicated that meta-
static disease is diagnosed between 63-99 months after
the initial diagnosis[7,18]. The incidence of distant
metastasis increases with time and has been reported as
13, 33, and 64% at 5, 10, and 15 years respectively[1].
Ecker and colleagues reported on fifteen patients with
forty-five lesions who were treated with GKS[8]. Four-
teen of these patients had previously undergone radio-
surgery. At a mean marginal dose of 16 Gy, 93% of
tumors had regressed or remained stable at the last fol-
low-up. In total, nine patients eventually died due to
metastatic disease and five patients died from tumor
burden. Kano et al. published a series consisting of
twenty patients who had undergone GKS for twenty-
nine tumors[20]. A tumor control rate of 72.4% was
reported at a mean follow-up period of 37.9 months.
The mean marginal dose to the tumor periphery was 15
Gy. The authors reported that twelve patients (60%)
were still alive at last follow-up while eight (40%) had
died at average of 62.6 months following GKS therapy.
In a study by Sun and colleagues, twenty-two patients
with fifty-eight foci underwent GKS at a mean tumor
margin dose of 13.5 Gy[11]. Radiological follow-up at 26
months showed that 25 foci (43.1%) nearly disappeared,
13 foci (22.4%) reduced in size, 14 foci (24.1%) remained
stable and 6 foci (10.3%) enlarged. The overall tumor
control rate was 89.7%. Intracranial metastases devel-
oped in 7 patients (31.8%) and extracranial metastases
developed in 3 patients (13.6%). Similarly, a much smal-
ler study by Iwai et al. in 2009 demonstrated 66.7%
tumor control at 34 months follow-up and a mean mar-
ginal dose of 13.7 Gy[19].
Recently, Olson and colleagues identified twenty-one
patients with twenty-eight lesions who were treated with
GKS[9]. These patients had received a mean marginal
dose of 17 Gy and at last follow-up, the tumor control
rate was 46.4%. The mean long term follow-up time of
69 months is greater than those of previous series asses-
sing the role of radiosurgery in the treatment of
hemangiopericytomas.
The Stanford Experience
Chang and Sakamoto’s series in 2003 confirmed those of
earlier reports, demonstrating tumor control in 75% of
the hemangiopericytomas treated during a mean 44
month follow-up period[6]. In this series, a LINAC
based radiosurgery system was used to treat four tumors
and CyberKnife radiosurgery was used to treat four
tumors in a total of eight patients. The mean dose rates
to tumor periphery in this series were slightly higher
(20.5 Gy) compared with those in other series (16.2 Gy).
The higher prescription dose, however, did not translate
to increased tumor control rates or radiosurgery related
complications.
The present series used CyberKnife to treat twenty-
four tumors. A tumor control rate of 81.8% was
achieved with a mean follow-up of 37 months. Although
the mean marginal dose is 21.2 Gy (the highest amongst
published series), adverse effects of radiotherapy were
not observed. Progression-free survival rate was 95%,
71.5%, and 71.5% at 1, 3, and 5 years after multiple CK
treatments. The 5-year survival rate after stereotactic
r a d i o s u r g e r yw a s8 1 % .A si st h ec a s ei no t h e rs e r i e s ,a l l
patients had previously undergone either single or mul-
tiple craniotomies for attempted gross total resection.
Conclusions from the Stanford study are similar to
those made by other groups. Stereotactic radiosurgery is
a focal, localized treatment modality and does not pre-
vent metastases, intracranial or otherwise. Metastases
outside the treatment area often developed within a few
years after initial treatment, but in one case was
reported to appear after twenty-two years[12]. Due to
the aggressive nature of hemangiopericytomas, initial
decreases in tumor size or even disappearance can be
followed by re-growth. This was observed in the present
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support the need for close clinical and radiographic fol-
low-up in this patient population.
Conclusion
Hemangiopericytomas are known for their aggressive
pathology, high recurrence rate, and propensity for dis-
tant metastasis. Surgical resection remains the initial
treatment option; however, postoperative stereotactic
radiosurgery has been shown to be effective in increas-
ing time to recurrence as well as patient survival. As
suggested by this series and previous reports, stereotac-
tic radiosurgery, including CyberKnife radiosurgery,
results in effective tumor control (tumor control rates
ranging from 46.4% to 100%, Stanford 81.8%). Close
clinical and radiographic follow-up is necessary due to
the high probability of local recurrence and distant
metastases. Because radiosurgery is a focal treatment, it
does not eliminate the possibility of regional or distant
metastases, which remain sources of significant morbid-
ity and mortality for these patients.
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